Completed PHASE2 INTERVENTIONAL 1-arm NCT03589469

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)

Sponsor: ADC Therapeutics S.A.

Conditions Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-cell Lymphoma Recurrent

Interventions Loncastuximab tesirine

Updated 28 times since 2018 Last updated: Aug 3, 2023 Started: Aug 1, 2018 Primary completion: May 24, 2020 Completion: Aug 9, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03589469, this PHASE2 trial focuses on Diffuse Large B-Cell Lymphoma Refractory and Diffuse Large B-cell Lymphoma Recurrent and remains completed. Sponsored by ADC Therapeutics S.A., it has been updated 28 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

28 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2023 — Jul 2024 [monthly]

Completed PHASE2
Sep 2022 — Sep 2023 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 23 earlier versions

Jul 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE2
Mar 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE2
Jan 2022 — Mar 2022 [monthly]

Active Not Recruiting PHASE2
Sep 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Active Not Recruiting PHASE2
Feb 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE2
Jul 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Mar 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE2
Jan 2020 — Mar 2020 [monthly]

Active Not Recruiting PHASE2
Dec 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2019 — Nov 2019 [monthly]

Recruiting PHASE2
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE2
May 2019 — Jun 2019 [monthly]

Recruiting PHASE2
Mar 2019 — May 2019 [monthly]

Recruiting PHASE2
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE2
Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE2
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Oct 2018 — Dec 2018 [monthly]

Recruiting PHASE2
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ADC Therapeutics S.A.

Data source: ADC Therapeutics S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Atlanta, United States , Bellinzona, Switzerland , Bologna, Italy , Charleston, United States , Cleveland, United States , Dallas, United States , Des Moines, United States , Duarte, United States , East Setauket, United States and 24 more locations